Clinical trials - Press Releases

Date	Title	Company
09-Aug-2022	The Global Biologics market is projected to grow at a CAGR of 8.82% By 2032: Visiongain Reports Ltd	Visiongain Reports Limited
09-Aug-2022	Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia	Karuna Therapeutics
09-Aug-2022	HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial	HUTCHMED
09-Aug-2022	U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)	Orion
09-Aug-2022	HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer	HUTCHMED
09-Aug-2022	EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer	EQRx
08-Aug-2022	Global Drug Discovery Services market is projected to grow at a CAGR of 15.17% by 2032; Visiongain Reports Ltd	Visiongain Reports Limited
08-Aug-2022	Global Genome Editing Technologies market is projected to grow at a CAGR of 15.96% by 2032: Visiongain Reports Ltd	Visiongain Reports Limited
08-Aug-2022	Oncology Applications of Epigenetics in Healthcare Offering Treatment to Cancer	P&S Intelligence
03-Aug-2022	Speaker Interview with Macarena Hernandez- Jimenez released for Oligonucleotide Therapeutics & Delivery Conference 2022	SAE Media Group
02-Aug-2022	Shionogi Begins Phase 3 Study in Japan of Akili’s Digital Treatment in Children with ADHD	Shionogi
02-Aug-2022	Immutep Reports new positive interim data from its Phase II Study of LAG-3 candidate, Eftilagimod Alpha, in second-line PD-X refractory NSCLC	Immutep
02-Aug-2022	HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China	HUTCHMED
01-Aug-2022	ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced	ViiV Healthcare
26-Jul-2022	SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)	SOTIO
25-Jul-2022	Novotech's Flexible Work Policy is Finalist in Best Workplace Flexibility Program "Excellence Award 2022"	Novotech Health Holdings Pte Ltd
22-Jul-2022	Personalized Nutrition Market Business Growth Analysis from 2019 - 2028	Axiom Market Research & Consulting
22-Jul-2022	uMotif expands leadership team to support growth in US and EU markets	uMotif
22-Jul-2022	Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	Takeda
21-Jul-2022	F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody	F-star Therapeutics